The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?

Ruth Peters, Hiroko H. Dodge, Sarah James, Gregory A. Jicha, Pierre Francois Meyer, Marcus Richards, A. David Smith, Hussein N. Yassine, Erin Abner, Atticus H. Hainsworth, Patrick G. Kehoe, Nigel Beckett, Craig S. Anderson, Kaarin J. Anstey

Research output: Contribution to journalArticlepeer-review

2 Scopus citations

Fingerprint

Dive into the research topics of 'The epidemiology is promising, but the trial evidence is weak. Why pharmacological dementia risk reduction trials haven't lived up to expectations, and where do we go from here?'. Together they form a unique fingerprint.

Medicine & Life Sciences

Social Sciences